NZ598801A - Use of the sparc microenvironment signature in the treatment of cancer - Google Patents
Use of the sparc microenvironment signature in the treatment of cancerInfo
- Publication number
- NZ598801A NZ598801A NZ598801A NZ59880110A NZ598801A NZ 598801 A NZ598801 A NZ 598801A NZ 598801 A NZ598801 A NZ 598801A NZ 59880110 A NZ59880110 A NZ 59880110A NZ 598801 A NZ598801 A NZ 598801A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tumor
- sparc
- antibody
- immunostaining
- histologic sections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27696909P | 2009-09-18 | 2009-09-18 | |
| PCT/US2010/049545 WO2011035274A1 (en) | 2009-09-18 | 2010-09-20 | Use of the sparc microenvironment signature in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598801A true NZ598801A (en) | 2014-07-25 |
Family
ID=43759058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598801A NZ598801A (en) | 2009-09-18 | 2010-09-20 | Use of the sparc microenvironment signature in the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120245089A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2478362B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013505268A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120092597A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102576016A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010295324B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012008316A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2774550A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL218642A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012003287A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ598801A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011035274A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201202657B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383358B2 (en) * | 2009-05-28 | 2013-02-26 | Abraxis Bioscience, Llc | Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
| AU2011261240A1 (en) * | 2010-06-03 | 2013-01-10 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| EP3539080B1 (en) * | 2016-11-10 | 2022-03-23 | F. Hoffmann-La Roche AG | Distance-based tumor classification |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5003621A (en) | 1989-11-02 | 1991-03-26 | Motorola, Inc. | Direct conversion FM receiver |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO2004085621A2 (en) * | 2003-03-20 | 2004-10-07 | Dana-Farber Cancer Institute, Inc. | Gene expression in breast cancer |
| ATE511550T1 (de) * | 2003-07-17 | 2011-06-15 | Pacific Edge Biotechnology Ltd | Marker zum nachweis von magenkrebs |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| GB0417740D0 (en) * | 2004-08-10 | 2004-09-08 | Uc3 | Methods and kit for the prognosis of breast cancer |
| AU2005297303B2 (en) * | 2004-10-19 | 2011-11-10 | Lsip, Llc | Novel diagnostic kit for malignant melanoma |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| WO2006112930A2 (en) * | 2005-02-18 | 2006-10-26 | Abraxis Bioscience, Inc. | Q3 sparc deletion mutant and uses thereof |
| RU2451521C2 (ru) * | 2006-06-16 | 2012-05-27 | Онкотерапи Сайенс, Инк. | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их |
| US9675578B2 (en) * | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| AU2008226283A1 (en) * | 2007-03-09 | 2008-09-18 | The University Of British Columbia | Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation |
| CN101678078B (zh) * | 2007-04-13 | 2014-12-10 | 阿布拉西斯生物科学公司 | Sparc及其使用方法 |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
-
2010
- 2010-09-20 JP JP2012529971A patent/JP2013505268A/ja active Pending
- 2010-09-20 EP EP10817999.5A patent/EP2478362B1/en active Active
- 2010-09-20 BR BR112012008316A patent/BR112012008316A2/pt not_active IP Right Cessation
- 2010-09-20 CN CN201080047076XA patent/CN102576016A/zh active Pending
- 2010-09-20 NZ NZ598801A patent/NZ598801A/en not_active IP Right Cessation
- 2010-09-20 WO PCT/US2010/049545 patent/WO2011035274A1/en not_active Ceased
- 2010-09-20 US US13/496,385 patent/US20120245089A1/en not_active Abandoned
- 2010-09-20 CA CA2774550A patent/CA2774550A1/en not_active Abandoned
- 2010-09-20 MX MX2012003287A patent/MX2012003287A/es not_active Application Discontinuation
- 2010-09-20 AU AU2010295324A patent/AU2010295324B2/en not_active Ceased
- 2010-09-20 KR KR1020127009670A patent/KR20120092597A/ko not_active Withdrawn
-
2012
- 2012-03-14 IL IL218642A patent/IL218642A0/en unknown
- 2012-04-12 ZA ZA2012/02657A patent/ZA201202657B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010295324A1 (en) | 2012-04-05 |
| US20120245089A1 (en) | 2012-09-27 |
| BR112012008316A2 (pt) | 2017-06-06 |
| WO2011035274A1 (en) | 2011-03-24 |
| CN102576016A (zh) | 2012-07-11 |
| IL218642A0 (en) | 2012-05-31 |
| AU2010295324B2 (en) | 2015-04-30 |
| JP2013505268A (ja) | 2013-02-14 |
| MX2012003287A (es) | 2012-08-03 |
| EP2478362B1 (en) | 2016-05-11 |
| ZA201202657B (en) | 2013-09-25 |
| EP2478362A1 (en) | 2012-07-25 |
| CA2774550A1 (en) | 2011-03-24 |
| EP2478362A4 (en) | 2013-09-11 |
| KR20120092597A (ko) | 2012-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084723A1 (es) | microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR | |
| Yu et al. | Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells | |
| WO2011112903A3 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients | |
| NZ607282A (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| AR080505A1 (es) | Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores | |
| WO2012054747A3 (en) | Methods and compositions for treating tumors using myeloid derived suppressor cells | |
| WO2013124815A3 (en) | Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof | |
| PH12014502548A1 (en) | Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands | |
| WO2012044696A3 (en) | Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature | |
| WO2008115750A3 (en) | Compositions and methods for the treatment of cancer | |
| Balvan et al. | Oxidative stress resistance in metastatic prostate cancer: renewal by self-eating | |
| AR087363A1 (es) | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres | |
| NZ609567A (en) | Markers of endothelial progenitor cells and uses thereof | |
| WO2012028961A3 (en) | Compositions and methods for treating friedreich's ataxia with interferon gamma | |
| WO2013177011A3 (en) | In vitro tumor in dish kit and method | |
| MX2013012648A (es) | Metodo para determinar hipoxia clinicamente relevante en cancer. | |
| WO2011149529A3 (en) | Cell-based preparations for wound management | |
| WO2012003493A3 (en) | Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use | |
| Tong et al. | Prognostic Significance of HMGA1 in Hepatocellular Carcinoma: Implications for Tumor Progression and Targeted Therapy | |
| CN202420940U (zh) | 一种免疫组织化学用载玻片 | |
| RU2009121722A (ru) | Способ диагностики опухолей поджелудочной железы | |
| Celebre et al. | Anaplastic meningioma with extensive single-cell infiltration: a potential role for epithelial-mesenchymal transformation in the progression of a meningothelial tumour? | |
| KAFEEL et al. | Lymphangioma of the ovary | |
| WO2013102118A3 (en) | Imageable patient tumors in mice | |
| WO2012174529A3 (en) | Methods for increasing the potency and efficacy of stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 SEP 2017 BY COMPUTER PACKAGES INC Effective date: 20141118 |
|
| LAPS | Patent lapsed |